Incidental cardiac uptake of 99mTc-diphosphonates is predictive of poor outcome: data from 9616 bone scintigraphies

[1]  P. Elliott,et al.  Quantitative SPECT/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis , 2021, EJNMMI Research.

[2]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization. , 2021, Circulation. Cardiovascular imaging.

[3]  M. Anselmino,et al.  The prevalence of TTR cardiac amyloidosis among patients undergoing bone scintigraphy , 2021, Journal of Nuclear Cardiology.

[4]  T. Heliö,et al.  Prognostic significance of incidental suspected transthyretin amyloidosis on routine bone scintigraphy , 2020, Journal of Nuclear Cardiology.

[5]  J. Butler,et al.  Emerging therapies in transthyretin amyloidosis – a new wave of hope after years of stagnancy? , 2020, European journal of heart failure.

[6]  Sanjiv J. Shah,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2—Diagnostic criteria and appropriate utilization , 2019, Journal of Nuclear Cardiology.

[7]  V. Murthy,et al.  ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI EXPERT CONSENSUS RECOMMENDATIONS FOR MULTIMODALITY IMAGING IN CARDIAC AMYLOIDOSIS: PART 1 OF 2-EVIDENCE BASE AND STANDARDIZED METHODS OF IMAGING. , 2019, Journal of cardiac failure.

[8]  M. Slama,et al.  Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease , 2019, Nature Reviews Neurology.

[9]  M. Emdin,et al.  Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis , 2019, Journal of Nuclear Cardiology.

[10]  M. Kürtüncü,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2019, Turkish Journal Of Neurology.

[11]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[12]  M. Sweetser,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[13]  K. Shah,et al.  Transthyretin Cardiac Amyloidosis , 2017, Current Cardiology Reports.

[14]  James C Moon,et al.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis , 2016, Circulation.

[15]  M. Skinner,et al.  Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study , 2016, Circulation.

[16]  F. Salvi,et al.  Identification of TTR-related subclinical amyloidosis with 99mTc-DPD scintigraphy. , 2014, JACC. Cardiovascular imaging.

[17]  F. Salvi,et al.  Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. , 2011, JACC. Cardiovascular imaging.

[18]  Keyur B Shah,et al.  Amyloidosis and the heart: a comprehensive review. , 2006, Archives of internal medicine.

[19]  F. Salvi,et al.  Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. , 2005, Journal of the American College of Cardiology.

[20]  V. R. McCready,et al.  Clinical significance of technetium-99m methylene diphosphonate myocardial uptake: association with carcinoma of the prostate , 1995, European Journal of Nuclear Medicine.

[21]  H. Hodkinson,et al.  The clinical significance of senile cardiac amyloidosis: a prospective clinico-pathological study. , 1977, The Quarterly journal of medicine.